

**IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE**

IMPAX LABORATORIES, INC.,
ASTRAZENECA AB, and
ASTRAZENECA UK LIMITED,

Plaintiffs,

V.

LANNETT HOLDINGS, INC., and
LANNETT COMPANY, INC.,

Defendants.

C.A. No. 14-984-RGA
(Consolidated)

NOTICE OF APPEAL

NOTICE IS HEREBY GIVEN that Lannett Company, Inc. and Lannett Holdings, Inc. (collectively “Lannett”), defendants in the above-captioned case, hereby appeal to the United States Court of Appeals for the Federal Circuit from the April 17, 2017 Final Judgment and Injunction (D.I. 174) that claims 4, 11, 12, and 14 of U.S. Patent No. 6,750,237 and claims 6, 14, and 15 of U.S. Patent No. 7,220,767 were not shown to be invalid, and that Plaintiffs Impax Laboratories, Inc., AstraZeneca AB, and AstraZeneca UK Limited, collectively, have standing to sue; from the August 24, 2016 Order on Motions in Limine (D.I. 116) granting plaintiffs’ request to exclude Lannett’s non-infringement defense that the claim term “zolmitriptan” excludes ionically bonded forms of zolmitriptan; and from the December 8, 2015 Claim Construction Order (D.I. 64).

Included herewith is payment of the filing fee (\$5.00) and the docketing fee (\$500.00) as required by 28 U.S.C. § 1917, Federal Circuit Rule 52(a), and Fed. R. App. P. 3(e).

FOX ROTHSCHILD LLP

Of Counsel:

Joseph F. Posillico, Esq. (admitted *pro hac vice*)
Frank T. Carroll, Esq. (admitted *pro hac vice*)
FOX ROTHSCHILD LLP
2000 Market Street, 20th Floor
Philadelphia, PA 19103-3222
(215) 299-2000

Michael W. Glynn, Esq. (admitted *pro hac vice*)
FOX ROTHSCHILD LLP
101 Park Ave., Suite 1700
New York, NY 10178
(646) 601-7634

/s/ Austen C. Endersby
Seth A. Niederman, Esquire (#4588)
Austen C. Endersby, Esquire (#5161)
Citizens Bank Center
919 North Market Street, Suite 300
Wilmington, DE 19801
(302) 654-7444
sniederman@foxrothschild.com
aendersby@foxrothschild.com

*Attorneys for Defendants Lannett Holdings,
Inc. and Lannett Company, Inc.*

Date: May 12, 2017